Profile data is unavailable for this security.
About the company
Orion Oyj is a Finland-based company engaged in the development, manufacture and marketing of pharmaceuticals and diagnostic tests. The Company operates, along with its subsidiaries, in two business segments: the Pharmaceuticals business segment develops, manufactures and markets pharmaceuticals and active pharmaceutical ingredients, and the Diagnostics business segment develops, manufactures and markets diagnostic tests. The Company’s business comprises two main divisions: Proprietary Products and Specialty Products. Its Proprietary Products consist of patented prescription products in three therapy areas: central nervous system diseases, oncology and critical care, and Easyhaler pulmonary drugs. The Company’s Specialty Products, which include the provision of generic prescription drugs and self-care products for basic healthcare. In addition the Company also produces veterinary medicines for pets and production animals.
- Revenue in EUR (TTM)1.63bn
- Net income in EUR313.30m
- Incorporated2006
- Employees4.03k
- LocationOrion OyjOrionintie 1AESPOO 02200FinlandFIN
- Phone+358 104261
- Fax+358 104264435
- Websitehttps://www.orionpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Co Ltd | 4.46bn | 235.91m | 8.15bn | 13.51k | 33.40 | 1.61 | 17.65 | 1.83 | 151.67 | 151.67 | 2,866.61 | 3,153.46 | 0.5537 | 0.7996 | 3.33 | 59,839,040.00 | 3.04 | 3.81 | 4.22 | 5.14 | 77.75 | 77.47 | 5.48 | 6.44 | 1.54 | -- | 0.2015 | 98.01 | 6.42 | 2.56 | 9.49 | -17.54 | -14.48 | 0.00 |
| Zydus Lifesciences Ltd | 2.43bn | 459.49m | 8.47bn | 27.92k | 18.43 | -- | 14.99 | 3.49 | 49.08 | 49.08 | 259.31 | -- | -- | -- | -- | 9,345,309.00 | -- | 10.92 | -- | 16.35 | 73.12 | 63.12 | 18.91 | 16.73 | -- | -- | -- | 17.81 | 18.90 | 10.27 | 17.96 | 30.92 | 13.63 | 25.74 |
| Jazz Pharmaceuticals PLC | 3.50bn | -310.47m | 8.51bn | 2.80k | -- | 2.55 | 31.80 | 2.43 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| WuXi XDC Cayman Inc | 621.22m | 162.03m | 8.86bn | 2.27k | 56.44 | 9.32 | 49.76 | 14.26 | 1.16 | 1.16 | 4.44 | 7.01 | 0.5687 | 21.58 | 3.31 | 2,823,422.00 | 14.83 | -- | 19.71 | -- | 33.01 | -- | 26.08 | -- | 2.14 | -- | 0.1225 | -- | 90.80 | -- | 277.24 | -- | -- | -- |
| Lupin Ltd | 2.43bn | 432.20m | 9.35bn | 19.98k | 20.25 | -- | 16.78 | 3.84 | 108.62 | 108.62 | 603.92 | -- | -- | -- | -- | 13,088,990.00 | -- | 4.53 | -- | 7.16 | 72.62 | 59.70 | 17.86 | 5.95 | -- | 183.80 | -- | 29.13 | 13.48 | 8.11 | 71.41 | -- | 20.11 | 14.87 |
| Avidity Biosciences Inc | 17.58m | -463.23m | 9.50bn | 391.00 | -- | 5.67 | -- | 540.34 | -4.17 | -4.17 | 0.1589 | 12.85 | 0.0111 | -- | 2.78 | 53,370.84 | -29.13 | -30.46 | -31.29 | -33.14 | -- | -- | -2,634.59 | -1,901.74 | -- | -- | 0.00 | -- | 13.99 | 36.27 | -51.87 | -- | 97.52 | -- |
| Orion Oyj | 1.63bn | 313.30m | 9.56bn | 4.03k | 30.44 | 9.37 | 26.33 | 5.87 | 2.23 | 2.23 | 11.59 | 7.24 | 0.9707 | 1.55 | 6.55 | 419,768.00 | 18.66 | 20.14 | 26.08 | 24.67 | 59.66 | 59.72 | 19.22 | 21.16 | 1.19 | 101.62 | 0.234 | 84.25 | 29.65 | 7.97 | 52.17 | 10.48 | 19.14 | 1.80 |
| Biomarin Pharmaceutical Inc | 2.61bn | 438.49m | 9.69bn | 3.04k | 22.44 | 1.90 | 19.07 | 3.72 | 2.67 | 2.67 | 15.82 | 31.53 | 0.4278 | 0.4512 | 3.95 | 1,017,764.00 | 7.20 | 2.18 | 8.04 | 2.46 | 81.32 | 76.43 | 16.82 | 6.07 | 3.10 | -- | 0.0897 | 0.00 | 17.97 | 10.86 | 154.62 | -- | -9.83 | -- |
| Dr Reddy's Laboratories Ltd | 3.23bn | 518.11m | 9.82bn | 26.94k | 18.98 | -- | 14.12 | 3.04 | 66.81 | 66.81 | 416.15 | -- | -- | -- | -- | 12,871,960.00 | -- | 12.15 | -- | 16.94 | 65.76 | 66.18 | 15.92 | 15.81 | -- | 19.79 | -- | 14.69 | 16.54 | 13.26 | 1.38 | 22.84 | 41.26 | 9.86 |
| Cipla Ltd | 2.64bn | 423.02m | 10.01bn | 30.31k | 23.67 | -- | 19.32 | 3.79 | 56.26 | 56.26 | 350.81 | -- | -- | -- | -- | 9,352,779.00 | -- | 11.89 | -- | 14.49 | 66.53 | 59.55 | 16.03 | 14.74 | -- | 96.40 | -- | 22.40 | 6.88 | 9.97 | 27.93 | 27.80 | 9.14 | 34.08 |
| Recordati Industria Chmc Frmctc SpA | 2.55bn | 404.39m | 10.02bn | 4.58k | 24.39 | 5.08 | 16.35 | 3.92 | 1.96 | 1.96 | 12.40 | 9.42 | 0.5377 | 1.81 | 4.87 | 557,416.80 | 8.51 | 10.50 | 10.71 | 13.46 | 67.66 | 69.89 | 15.83 | 19.98 | 1.16 | 8.30 | 0.5651 | 36.98 | 12.45 | 9.58 | 7.01 | 2.46 | 13.94 | 4.90 |
| Neurocrine Biosciences Inc | 2.41bn | 403.25m | 10.50bn | 2.00k | 26.62 | 3.82 | 24.49 | 4.35 | 4.66 | 4.66 | 27.91 | 32.50 | 0.6851 | 0.8244 | 4.91 | 1,430,250.00 | 11.46 | 9.00 | 13.48 | 10.78 | 98.18 | 98.32 | 16.73 | 13.51 | 3.30 | -- | 0.00 | -- | 21.45 | 22.29 | 40.23 | 3.28 | 25.55 | -- |
| Elanco Animal Health Inc | 3.87bn | 30.33m | 10.52bn | 9.00k | 350.88 | 1.85 | 17.69 | 2.72 | 0.0716 | 0.0716 | 9.23 | 13.58 | 0.3422 | 1.24 | 5.30 | 510,111.10 | 0.2683 | -2.71 | 0.2993 | -3.02 | 54.96 | 54.72 | 0.7841 | -9.52 | 1.23 | 1.30 | 0.3735 | -- | 0.4981 | 7.65 | 127.46 | 37.85 | -3.99 | -- |
| Financiere de Tubize SA | 0.00 | 92.74m | 10.59bn | -- | 114.23 | 5.47 | 114.23 | -- | 2.08 | 2.08 | 0.00 | 43.49 | 0.00 | -- | -- | -- | 4.81 | 5.68 | 4.85 | 5.89 | -- | -- | -- | 230.34 | -- | -- | 0.00 | 30.18 | -- | -- | 2.22 | -20.50 | -- | 10.90 |
Data as of Feb 16 2026. Currency figures normalised to Orion Oyj's reporting currency: Euro EUR
23.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Keskin�inen El�kevakuutusyhti� Ilmarinenas of 30 Sep 2025 | 4.65m | 4.24% |
| Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 30 Sep 2025 | 4.05m | 3.69% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 4.03m | 3.68% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 2.30m | 2.10% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 2.22m | 2.03% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 2.12m | 1.93% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 1.84m | 1.68% |
| Keskin�inen Ty�el�kevakuutusyhti� Eloas of 30 Sep 2025 | 1.78m | 1.63% |
| Geode Capital Management LLCas of 12 Feb 2026 | 1.50m | 1.37% |
| OP Asset Management Ltd.as of 30 Jun 2025 | 1.33m | 1.22% |
More ▼
Data from 31 Jul 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
